Literature DB >> 20801607

Endothelial cells are susceptible to rapid siRNA transfection and gene silencing ex vivo.

Nicholas D Andersen1, Atish Chopra, Thomas S Monahan, Junaid Y Malek, Monica Jain, Leena Pradhan, Christiane Ferran, Frank W LoGerfo.   

Abstract

BACKGROUND: Endothelial gene silencing via small interfering RNA (siRNA) transfection represents a promising strategy for the control of vascular disease. Here, we demonstrate endothelial gene silencing in human saphenous vein using three rapid siRNA transfection techniques amenable for use in the operating room.
METHODS: Control siRNA, Cy5 siRNA, or siRNA targeting glyceraldehyde-3-phosphate dehydrogenase (GAPDH) or endothelial specific nitric oxide synthase (eNOS) were applied to surplus human saphenous vein for 10 minutes by (i) soaking, (ii) applying 300 mm Hg hyperbaric pressure, or (iii) 120 mm Hg luminal distending pressure. Transfected vein segments were maintained in organ culture. siRNA delivery and gene silencing were assessed by tissue layer using confocal microscopy and immunohistochemistry.
RESULTS: Distending pressure transfection yielded the highest levels of endothelial siRNA delivery (22% pixels fluorescing) and gene silencing (60% GAPDH knockdown, 55% eNOS knockdown) as compared with hyperbaric (12% pixels fluorescing, 36% GAPDH knockdown, 30% eNOS knockdown) or non-pressurized transfections (10% pixels fluorescing, 30% GAPDH knockdown, 25% eNOS knockdown). Cumulative endothelial siRNA delivery (16% pixels fluorescing) and gene silencing (46% GAPDH knockdown) exceeded levels achieved in the media/adventitia (8% pixels fluorescing, 24% GAPDH knockdown) across all transfection methods.
CONCLUSION: Endothelial gene silencing is possible within the time frame and conditions of surgical application without the use of transfection reagents. The high sensitivity of endothelial cells to siRNA transfection marks the endothelium as a promising target of gene therapy in vascular disease.
Copyright © 2010 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20801607      PMCID: PMC2994949          DOI: 10.1016/j.jvs.2010.06.169

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  28 in total

1.  Quantitative immunohistochemistry by measuring cumulative signal strength using commercially available software photoshop and matlab.

Authors:  K A Matkowskyj; D Schonfeld; R V Benya
Journal:  J Histochem Cytochem       Date:  2000-02       Impact factor: 2.479

2.  Comparison of gene silencing in human vascular cells using small interfering RNAs.

Authors:  Nicholas D Andersen; Thomas S Monahan; Junaid Y Malek; Monica Jain; Soizic Daniel; Lena D Caron; Leena Pradhan; Christiane Ferran; Frank W Logerfo
Journal:  J Am Coll Surg       Date:  2007-03       Impact factor: 6.113

3.  Histologic fate and endothelial changes of distended and nondistended vein grafts.

Authors:  J R Ramos; K Berger; P B Mansfield; L R Sauvage
Journal:  Ann Surg       Date:  1976-03       Impact factor: 12.969

4.  Intimal proliferation in an organ culture of human saphenous vein.

Authors:  A A Soyombo; G D Angelini; A J Bryan; B Jasani; A C Newby
Journal:  Am J Pathol       Date:  1990-12       Impact factor: 4.307

5.  The Editor's Roundtable: Endothelial dysfunction in cardiovascular disease.

Authors:  Vincent E Friedewald; Thomas D Giles; James L Pool; Clyde W Yancy; William C Roberts
Journal:  Am J Cardiol       Date:  2008-08-15       Impact factor: 2.778

6.  Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues.

Authors:  M J Mann; G H Gibbons; H Hutchinson; R S Poston; E G Hoyt; R C Robbins; V J Dzau
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

7.  Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial.

Authors:  M J Mann; A D Whittemore; M C Donaldson; M Belkin; M S Conte; J F Polak; E J Orav; A Ehsan; G Dell'Acqua; V J Dzau
Journal:  Lancet       Date:  1999-10-30       Impact factor: 79.321

8.  A clinical technique for prevention of spasm and preservation of endothelium in saphenous vein grafts.

Authors:  F W LoGerfo; C C Haudenschild; W C Quist
Journal:  Arch Surg       Date:  1984-10

9.  siRNA relieves chronic neuropathic pain.

Authors:  Gabriele Dorn; Sadhana Patel; Glen Wotherspoon; Maja Hemmings-Mieszczak; Jane Barclay; Francois J C Natt; Pierre Martin; Stuart Bevan; Alyson Fox; Pam Ganju; William Wishart; Jonathan Hall
Journal:  Nucleic Acids Res       Date:  2004-03-16       Impact factor: 16.971

Review 10.  The role of endothelium in cardiovascular homeostasis and diseases.

Authors:  G M Rubanyi
Journal:  J Cardiovasc Pharmacol       Date:  1993       Impact factor: 3.105

View more
  3 in total

1.  Gene silencing in human aortic smooth muscle cells induced by PEI-siRNA complexes released from dip-coated electrospun poly(ethylene terephthalate) grafts.

Authors:  Christoph S Nabzdyk; Maggie C Chun; Hunter S Oliver-Allen; Saif G Pathan; Matthew D Phaneuf; Jin-Oh You; Leena K Pradhan-Nabzdyk; Frank W LoGerfo
Journal:  Biomaterials       Date:  2014-01-04       Impact factor: 12.479

2.  Intraluminal delivery of thrombospondin-2 small interfering RNA inhibits the vascular response to injury in a rat carotid balloon angioplasty model.

Authors:  Thomas C F Bodewes; Joel M Johnson; Michael Auster; Cindy Huynh; Sriya Muralidharan; Mauricio Contreras; Frank W LoGerfo; Leena Pradhan-Nabzdyk
Journal:  FASEB J       Date:  2016-09-26       Impact factor: 5.191

Review 3.  RNAi therapy to the wall of arteries and veins: anatomical, physiologic, and pharmacological considerations.

Authors:  Christoph S Nabzdyk; Leena Pradhan-Nabzdyk; Frank W LoGerfo
Journal:  J Transl Med       Date:  2017-07-28       Impact factor: 5.531

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.